[{"data":1,"prerenderedAt":233},["ShallowReactive",2],{"drug-colchicine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":37,"contraindications":116,"warnings":126,"renal":127,"monitoring":128,"interactions":129,"review":130,"examples":132,"atc":158,"iran":160,"links":176,"populations":193,"usApproval":228},"colchicine",1,{"fa":7,"en":8},"کلشی‌سین","Colchicine","musculoskeletal",{"fa":11,"en":12},"ضدالتهاب نقرس","Anti-gout agent",[14],{"name":15,"market":16},"Colcrys","US",[18,19,20,21],"colcrys","کلشیسین","کلشی سین","کلچیسین",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":32,"refs":33},"tab-0-6","tablet","oral","0.6 mg tablet (scored)",{"amount":29,"unit":30,"perUnit":25,"scored":31},0.6,"mg",true,[16],[34],{"source":35,"section":36},"fda-colcrys","3",[38,64,79],{"id":39,"disease":40,"label":41,"population":44,"type":48,"unit":30,"dose":49,"refs":51,"durationDays":54,"notes":55},"flare","gout",{"fa":42,"en":43},"حمله نقرس — ۱٫۲ mg و یک ساعت بعد ۰٫۶ mg","Gout flare — 1.2 mg, then 0.6 mg one hour later",{"minAge":45},{"value":46,"unit":47},18,"year","fixed",{"perDose":50,"dosesPerDay":5},1.2,[52],{"source":35,"section":53},"2.1",{"min":5,"max":5},[56],{"text":57,"refs":60},{"fa":58,"en":59},"در اولین نشانه حمله. در بیمارانی که دوز پیشگیری + مهارکننده CYP3A4 می‌گیرند توصیه نمی‌شود.","At the first sign of a flare. Not recommended in patients on prophylactic dose plus CYP3A4 inhibitors.",[61,62],{"source":35,"section":53},{"source":35,"section":63},"2.4",{"id":65,"disease":40,"label":66,"population":69,"type":48,"unit":30,"dose":72,"refs":73,"limits":75},"prophylaxis",{"fa":67,"en":68},"پیشگیری از حمله نقرس — بالای ۱۶ سال: ۰٫۶ mg یک یا دو بار در روز","Gout flare prophylaxis — >16 y: 0.6 mg once or twice daily",{"minAge":70},{"value":71,"unit":47},16,{"perDose":29,"dosesPerDay":5},[74],{"source":35,"section":53},{"maxPerDay":50,"refs":76},[77],{"source":35,"section":78},"2",{"id":80,"disease":80,"label":81,"population":84,"type":87,"unit":30,"dose":88,"refs":103,"notes":108},"fmf",{"fa":82,"en":83},"FMF — بر اساس سن (۴ سال به بالا)","FMF — by age (≥4 y)",{"minAge":85},{"value":86,"unit":47},4,"ageBand",{"bands":89},[90,95,100],{"minAge":91,"maxAge":92,"perDose":94,"dosesPerDay":5},{"value":86,"unit":47},{"value":93,"unit":47},6,0.3,{"minAge":96,"maxAge":97,"perDose":99,"dosesPerDay":5},{"value":93,"unit":47},{"value":98,"unit":47},13,0.9,{"minAge":101,"maxAge":102,"perDose":50,"dosesPerDay":5},{"value":98,"unit":47},null,[104,106],{"source":35,"section":105},"2.2",{"source":35,"section":107},"2.3",[109],{"text":110,"refs":113},{"fa":111,"en":112},"دوز شروع پایین محدوده: ۴ تا ۶ سال ۰٫۳ تا ۱٫۸؛ ۶ تا ۱۲ سال ۰٫۹ تا ۱٫۸؛ بالای ۱۲ سال و بزرگسال ۱٫۲ تا ۲٫۴ mg\u002Fday، یک یا دو نوبت؛ تغییر ۰٫۳ mg\u002Fday.","Shown is the low end: 4–6 y 0.3–1.8; 6–12 y 0.9–1.8; >12 y and adults 1.2–2.4 mg\u002Fday, once or twice daily; adjust by 0.3 mg\u002Fday.",[114,115],{"source":35,"section":107},{"source":35,"section":78},[117],{"id":118,"severity":119,"text":120,"refs":123},"ci","block",{"fa":121,"en":122},"نارسایی کلیه یا کبد همراه مهارکننده‌های P-gp یا قوی CYP3A4 (سمیت کشنده).","Renal or hepatic impairment together with P-gp or strong CYP3A4 inhibitors (fatal toxicity).",[124],{"source":35,"section":125},"4",[],[],[],[],{"status":131,"reviewer":102,"date":102},"unverified",[133,139,142,147,153],{"regimen":39,"formulation":24,"input":134,"expect":137},{"ageYears":135,"weightKg":136},50,85,{"perDose":50,"tabletsPerDoseRounded":138},2,{"regimen":65,"formulation":24,"input":140,"expect":141},{"ageYears":135,"weightKg":136},{"perDose":29},{"regimen":80,"formulation":24,"input":143,"expect":145},{"ageYears":144,"weightKg":46},5,{"perDose":94,"tabletsPerDoseRounded":146},0.5,{"regimen":80,"formulation":24,"input":148,"expect":151},{"ageYears":149,"weightKg":150},8,25,{"perDose":99,"tabletsPerDoseRounded":152},1.5,{"regimen":80,"formulation":24,"input":154,"expect":157},{"ageYears":155,"weightKg":156},30,70,{"perDose":50},[159],"M04AC01",{"status":161,"forms":162,"refs":171},"registered",[163,167],{"code":164,"en":165,"fa":166},"00348","COLCHICINE 1MG TAB","قرص کلشی‌سین ۱ میلی‌گرم",{"code":168,"en":169,"fa":170},"07262","COLCHICINE 500MCG TAB","قرص کلشی‌سین ۵۰۰ میکروگرم",[172],{"source":173,"section":174,"url":175},"darooyab-generic","G-757\u002FColchicine","https:\u002F\u002Fwww.darooyab.ir\u002FG-757\u002FColchicine",[177,181,185,188,191],{"kind":178,"url":179,"label":180},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022352","NDA022352",{"kind":182,"url":183,"label":184},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d6adc880-5499-4691-93f3-27c87902d5fc","FDA Colcrys",{"kind":186,"url":187,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682711.html",{"kind":189,"url":190,"label":159},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=M04AC01",{"kind":192,"url":175,"label":8},"darooyab",{"pregnancy":194,"lactation":203,"pediatric":211,"geriatric":220},{"level":195,"text":196,"quote":199,"refs":200},"caution",{"fa":197,"en":198},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Pregnancy Category C.",[201],{"source":35,"section":202},"8.1",{"level":195,"text":204,"quote":207,"refs":208},{"fa":205,"en":206},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Caution should be exercised, and breastfeeding infants should be observed for adverse effects when COLCRYS is administered to a nursing woman.",[209],{"source":35,"section":210},"8.3",{"level":212,"text":213,"quote":216,"refs":217},"not-established",{"fa":214,"en":215},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Gout is rare in pediatric patients; safety and effectiveness of colchicine in pediatric patients has not been established.",[218],{"source":35,"section":219},"8.4",{"level":195,"text":221,"quote":224,"refs":225},{"fa":222,"en":223},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient with gout should be cautious, reflecting the greater frequency of decreased renal function, concomitant disease or other drug therapy [see Dose Modification for Coadministration of Interacting Drugs (2.4) and Pharmacokinetics (12.3) ] .",[226],{"source":35,"section":227},"8.5",{"kind":229,"refs":230,"id":180},"NDA",[231],{"source":35,"section":232},"SPL approval \u002F marketing category",1792444711379]